摘要
目的探讨胆管癌患者的血清肿瘤标志物糖类抗原(CA)19-9的变化情况,并评价其在临床中的意义。方法采取化学发光免疫法对沈阳军区总医院2010年1月～2010年12月收治的50例胆管癌患者(研究组)和同期的50例胆道良性疾病患者(对照1组)以及50名健康对象(对照2组)血清中CA19-9含量进行测定。结果通过三组的对比分析,研究组患者的CA19-9含量为(288.6±45.6)U/mL,对照1组的CA19-9含量为(92.3±12.4)U/mL,对照2组CA19-9含量为(17.4±5.6)U/mL,研究组患者的CA19-9含量明显高于对照1组和对照2组的CA19-9含量,三组数据比较差异有统计学有意义(P<0.05);胆管癌Ⅰ期患者CA19-9含量为(118.6±47.5)U/mL,Ⅱ-Ⅲ期患者CA19-9含量为(222.3±54.4)U/mL,Ⅳ期患者CA19-9含量为(452.4±55.6)U/mL,三组数据比较差异有统计学有意义(P<0.05)。结论临床中对于测定CA19-9能够对胆管癌患者的筛查和临床分期具有一定的诊断效果,而且可以依据不同的含量情况进行判断临床分期情况,在临床中具有较好的应用价值。
Objective To investigate the changes of cholangiocarcinoma in patients with serum tumor markers carbo hydrate antigen 19-9,and to evaluate its clinical significance.Methods A chemiluminescent immunoassay the same period in our hospital from January 2010 to December 2010 were treated 50 cases of cholangiocarcinoma patients（study group） and 50 cases of benign biliary diseases（control group 1） and 50 healthy subjects（control group 2） serum carbohydrate antigen 19-9 were determined.Results A comparative analysis of three groups,CA19-9 levels in the patients of the study group of（288.6±45.6） U/mL,control group 1 CA19-9 levels of（92.3 ± 12.4） U/mL,control group 2 CA19-9 content of（17.4±5.6） U/mL,content of CA19-9 in patients of the study group of CA19-9 was significantly higher than the control group 1 and control group 2,three sets of data compared with a significant difference（P 0.05）,statistically meaningful;of cholangiocarcinoma I patients CA19-9 levels of（118.6 ±47.5） U/mL,Ⅱ-Ⅲ patients with CA19-9 levels of（222.3 ±54.4） U/mL,stage IV patients CA19-9 content of（452.4 ±55.6） U/mL,three sets of data compared with a significant difference（P 0.05） and statistically meaningful.Conclusion The clinical determination of carbohydrate antigen 19-9 to patients with bile duct cancer screening and clinical staging diagnosis effect,and can be carried out to determine the clinical stage of depending on the content,has good clinical application value.
出处
《中国医药导报》
CAS
2013年第23期10-12,共3页
China Medical Herald
基金
江苏省医学科研立项课题(编号H201116)
关键词
胆管癌
糖类抗原19-9
动态变化
临床意义
Bile duct cancer
Carbohydrate antigen 19-9
Dynamic change
Clinical significance
